Centiva Capital LP Has $284,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Centiva Capital LP lessened its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 70.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,858 shares of the biotechnology company's stock after selling 4,487 shares during the period. Centiva Capital LP's holdings in Biogen were worth $284,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Brevan Howard Capital Management LP raised its stake in shares of Biogen by 564.6% in the fourth quarter. Brevan Howard Capital Management LP now owns 7,138 shares of the biotechnology company's stock worth $1,092,000 after acquiring an additional 6,064 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Biogen by 49.6% in the 4th quarter. Captrust Financial Advisors now owns 9,712 shares of the biotechnology company's stock valued at $1,485,000 after buying an additional 3,218 shares during the period. Cary Street Partners Financial LLC acquired a new stake in Biogen during the 4th quarter worth $266,000. Brown Advisory Inc. grew its position in shares of Biogen by 4.3% in the 4th quarter. Brown Advisory Inc. now owns 347,566 shares of the biotechnology company's stock valued at $53,150,000 after purchasing an additional 14,339 shares during the period. Finally, BNP Paribas raised its holdings in shares of Biogen by 14.9% during the fourth quarter. BNP Paribas now owns 804 shares of the biotechnology company's stock worth $123,000 after acquiring an additional 104 shares during the period. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

BIIB has been the subject of several recent analyst reports. Wells Fargo & Company dropped their target price on shares of Biogen from $165.00 to $140.00 and set an "equal weight" rating on the stock in a report on Thursday, February 13th. Bank Of America (Bofa) decreased their target price on Biogen from $178.00 to $163.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 11th. Citigroup lowered their target price on Biogen from $160.00 to $145.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 price target for the company. Finally, Piper Sandler lowered their price objective on Biogen from $135.00 to $115.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Twenty analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $191.30.

Biogen Stock Up 1.5%

Shares of BIIB stock traded up $1.89 on Friday, reaching $125.59. 1,803,229 shares of the stock were exchanged, compared to its average volume of 1,379,278. The business's 50 day moving average price is $126.32 and its 200 day moving average price is $142.98. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $18.40 billion, a price-to-earnings ratio of 11.22, a PEG ratio of 1.51 and a beta of 0.12. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The company had revenue of $2.43 billion for the quarter, compared to analyst estimates of $2.25 billion. During the same period in the prior year, the business earned $3.67 earnings per share. Biogen's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This trade represents a 43.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.